Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4083012 | 0.91 | GBA2 (0.43) | GBA1GBA2BCHE | |
| SCHEMBL26050252 | 0.83 | GBA1 (0.45) | GBA1HTR1AGBA2SMN1; SMN2KCNK3 | |
| SCHEMBL26050348 | 0.74 | GBA2 (0.47) | GBA1GBA2 | |
| SCHEMBL4083015 | 0.73 | LMNA (0.33) | GBA1GBA2LMNABCHE | |
| SCHEMBL12191654 | 0.69 | ACE (0.44) | GBA1SMN1; SMN2KCNK3LMNA | |
| SCHEMBL5701854 | 0.69 | ACE (0.44) | GBA1SMN1; SMN2KCNK3LMNA | |
| SCHEMBL5702197 | 0.69 | ACE (0.44) | GBA1SMN1; SMN2KCNK3LMNA | |
| SCHEMBL23374790 | 0.67 | SMN1; SMN2 (0.46) | GBA1HTR1ASMN1; SMN2KCNK3LMNA | |
| SCHEMBL12191642 | 0.66 | GBA1 (0.51) | GBA1HTR1AGBA2SMN1; SMN2KCNK3 | |
| SCHEMBL8894199 | 0.66 | GBA1 (0.51) | GBA1HTR1AGBA2SMN1; SMN2KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365093-B2 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-7208517-B1 | Endothelin antagonists | ABBOTT LABORTORIES (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060229280-A1 | Endothelin antagonists | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
| US-6946481-B1 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2005-09-20 | — | — | US | disclosed |
| US-6462194-B1 | Endothelin antagonists | ABBOTT LABORATORIES | 2002-10-08 | — | — | US | disclosed |
| US-6380241-B1 | FOR THERAPY OF CORONARY ANGINA, CEREBRAL VASOSPASM, ACUTE AND CHRONIC RENAL FAILURE, GASTRIC ULCERATION, CYCLOSPORIN-INDUCED NEPHROTOXICITY, ENDOTOXIN-INDUCED TOXICITY, ASTHMA, LPL-RELATED LIPOPROTEIN DISORDERS, PROLIFERATIVE DISEASES | ABBOTT LABORATORIES | 2002-04-30 | — | — | US | disclosed |
| WO-2002017912-A1 | ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6162927-A | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2000-12-19 | — | — | US | disclosed |
| EP-0776324-A1 | ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1997-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229280-A1 | Endothelin antagonists | EDNRA, EDNRB, ECE1 | GBA1 3358/4885HTR1A 464/4885GBA2 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.